Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

v3.21.2
Acquisitions - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Oct. 01, 2020
USD ($)
Sep. 09, 2020
USD ($)
Sep. 08, 2020
USD ($)
Apr. 01, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Pfenex              
Business Acquisition [Line Items]              
Consideration transferred in acquisition $ 465,100,000            
Cash payments for acquisition 429,600,000            
Contingent earn-out payment 77,800,000            
Fair value of contingent earn-out payment 37,000,000            
Post-combination expense 1,500,000            
Gross payments to acquire business attributable to vested portion of stock options $ 17,300,000            
Cash to settle unvested stock options recognized as share-based compensation expense             $ 8,700,000
Weighted-average estimated useful life of finite-lived intangible assets acquired 13 years            
Deferred tax liability acquired in connection with the acquired intangibles $ (52,730,000)            
Deferred revenue acquired (3,908,000)            
Pfenex | Contractual Relationships              
Business Acquisition [Line Items]              
Finite-lived intangible assets acquired $ 362,000,000            
Weighted-average estimated useful life of finite-lived intangible assets acquired 12 years 10 months 24 days            
Pfenex | Core Technology              
Business Acquisition [Line Items]              
Finite-lived intangible assets acquired $ 23,000,000            
Pfenex | Core Technology | Minimum              
Business Acquisition [Line Items]              
Discount rate used to value intangible assets acquired (as a percent) 12.00%            
Pfenex | Core Technology | Maximum              
Business Acquisition [Line Items]              
Discount rate used to value intangible assets acquired (as a percent) 15.00%            
Pfenex | Discount Rate              
Business Acquisition [Line Items]              
Contingent consideration liability, measurement input (as a percent) 0.071            
Taurus              
Business Acquisition [Line Items]              
Consideration transferred in acquisition   $ 5,100,000          
Cash payments for acquisition   4,600,000          
Contingent earn-out payment   0          
Holdback from acquisition   500,000          
Tangible assets acquired   50,000.00          
Taurus | Contingent Value Right for Internal Research and Development              
Business Acquisition [Line Items]              
Contingent earn-out payment   4,500,000          
Taurus | Contingent Value Right on Product Revenues              
Business Acquisition [Line Items]              
Contingent earn-out payment   $ 25,000,000          
Proportion of milestone payments (as a percent)   25.00%          
Taurus | Core Technology              
Business Acquisition [Line Items]              
Finite-lived intangible assets acquired   $ 5,000,000          
Weighted-average estimated useful life of finite-lived intangible assets acquired   10 years          
xCella              
Business Acquisition [Line Items]              
Consideration transferred in acquisition     $ 7,100,000        
Contingent earn-out payment     0        
Holdback from acquisition     500,000        
Tangible assets acquired     200,000        
Liabilities assumed     (100,000)        
Deferred tax liability acquired in connection with the acquired intangibles     (800,000)        
xCella | Earnout Rights for Partner Research and Development              
Business Acquisition [Line Items]              
Contingent earn-out payment     5,000,000        
Earnout rights recognized         $ 500,000 $ 700,000  
xCella | Milestone Payments              
Business Acquisition [Line Items]              
Contingent earn-out payment     $ 25,750,000        
Proportion of milestone payments (as a percent)     25.00%        
xCella | Core Technology              
Business Acquisition [Line Items]              
Finite-lived intangible assets acquired     $ 7,800,000        
Weighted-average estimated useful life of finite-lived intangible assets acquired     15 years        
Icagen              
Business Acquisition [Line Items]              
Consideration transferred in acquisition       $ 19,900,000      
Cash payments for acquisition       15,100,000      
Contingent earn-out payment       25,000,000      
Fair value of contingent earn-out payment       4,800,000      
Finite-lived intangible assets acquired       $ 12,800,000      
Weighted-average estimated useful life of finite-lived intangible assets acquired       9 years 8 months 12 days      
Tangible assets acquired       $ 1,800,000      
Liabilities assumed       (800,000)      
Acquisition related costs       0      
Deferred revenue acquired       (3,700,000)      
Deferred tax assets acquired       800,000      
Goodwill acquired       9,000,000      
Icagen | Core Technology              
Business Acquisition [Line Items]              
Finite-lived intangible assets acquired       $ 1,700,000      
Weighted-average estimated useful life of finite-lived intangible assets acquired       10 years      
Discount rate used to value intangible assets acquired (as a percent)       17.00%      
Icagen | Customer Relationships              
Business Acquisition [Line Items]              
Finite-lived intangible assets acquired       $ 11,100,000      
Weighted-average estimated useful life of finite-lived intangible assets acquired       9 years 7 months 6 days      
Discount rate used to value intangible assets acquired (as a percent)       17.00%